Silence Therapeutics plc (SLN) stock
SLNNasdaqPharmaceutical PreparationsAlso trades as SLNCF
$19.83+0.03 (+0.15%)
Close on Nov 13, 2026Market cap $936.90MP/E –Yield –
Silence Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Silence Therapeutics's gross margin for the twelve months ending Sep 30, 2026 was 95.0%. For fiscal 2025 it was 61.5%, against 72.7% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 61.5% | −11.2 |
| FY2024 | Dec 31, 2024 | 72.7% | +13.4 |
| FY2023 | Dec 31, 2023 | 59.3% | +21.5 |
| FY2022 | Dec 31, 2022 | 37.8% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | 97.4% | +35.4 |
| Q4 FY2025 | Dec 31, 2025 | 64.7% | −27.2 |
| Q3 FY2025 | Sep 30, 2025 | 59.7% | +202.7 |
| Q2 FY2025 | Jun 30, 2025 | 62.1% | +402.9 |
| Q1 FY2025 | Mar 31, 2025 | 62.0% | −20.2 |
| Q4 FY2024 | Dec 31, 2024 | 91.9% | – |
| Q3 FY2024 | Sep 30, 2024 | -142.9% | – |
| Q2 FY2024 | Jun 30, 2024 | -340.9% | – |
| Q1 FY2024 | Mar 31, 2024 | 82.2% | – |
See a number that looks wrong?